Bcl-2 Inhibition With ABT-199 in CLL, Lymphomas

For High-Definition, Click

ABT-199 is an orally bioavailable selective inhibitor of the Bcl-2 protein, which is commonly overexpressed in a variety of lymphoid malignancies, notes Brad S. Kahl, MD. The agent is a BH3 mimetic, which improves efficacy while lowering the thrombocytopenia seen with previous Bcl-2 inhibitors. In early phase I findings, single-agent ABT-199 induced an overall response rate of near 85% in chemotherapy refractory patients with bulky chronic lymphocytic leukemia. Given the different mechanisms of action, the combination of the BTK inhibitor ibrutinib and ABT-199 could be a dynamic combination, Kahl believes.

High-grade B-cell lymphomas with dual chromosomal rearrangements, or double hit lymphomas, remain challenging to treat, Kahl notes. In general, this population has a rearrangement in both MYC and Bcl-2. To address this unmet need, trials are looking at the combination of ABT-199 with R-CHOP for patients with large cell lymphoma, Kahl states.

Related Videos
Sattva S. Neelapu, MD
David L. Porter, MD
Sattva S. Neelapu, MD
Julie M. Vose, MD, MBA
Lakshmi Nayak, MD
John Burke, MD
Jakub Svoboda, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Mazyar Shadman, MD, MPH
Ben Levy, MD, and Yan Leyfman, MD